Heart failure & cardiomyopathiesSecondary analysis
Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial
- Secondary analysis of the FINEARTS-HF randomised trial
- pre-specified analysis
Authors' conclusion
In FINEARTS-HF, >90% of patients with HFmrEF/HFpEF met the criteria for polypharmacy or hyper-polypharmacy, and these patients faced excess risks of cardiovascular events. Finerenone safely reduced cardiovascular death and total HF events across a broad range of baseline medication use.
Study context
- Population
- Patients with HFmrEF/HFpEF in the FINEARTS-HF trial
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo by baseline medication count
- Polypharmacyn = 3,588
- Hyper-polypharmacyn = 1,878
- Primary endpoint
- Composite of:
- CV death
- Total HF events
Primary result
As reported in the abstract
CV death and total HF events, by medication category
- Finerenone benefit consistent across total medication count
- P for interaction = 0.94
Safety
Serious adverse events and study drug discontinuation
- Not more frequent with finerenone vs placebo, regardless of polypharmacy category
Original publication
Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial. Eur J Heart Fail. Published 10 February 2026. doi:10.1093/ejhf/xuag030
Summarised from the published abstract; every number is checked against it